Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

From plastic-eating plants to AI-guided therapies, iGEM 2025 reveals the innovations defining the future of synthetic biology ...

The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.

Discover how biosimilars in Europe expand access, cut costs, and strengthen healthcare systems for a more sustainable future.

We spoke to five Australian companies in Vienna seeking collaborators and capital at the BIO Europe partnering conference.

Based in Switzerland, Alentis Therapeutics is a clinical-stage biotech company developing first-in-class therapies that target Claudin-1 (CLDN1), a tight-junction protein abnormally expressed in ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech ...

I am the Director of Editorial at Labiotech. Born and raised in Western Australia, I earned undergraduate degrees in International Studies and Social Science at the University of South Australia ...

Aiolos Bio has emerged as a significant player in the biopharmaceutical industry, with a focus on developing treatments for respiratory and inflammatory diseases. The company’s launch in 2023, backed ...